WDNA Fees and Costs — WisdomTree BioRevolution Fund
Data updated: 2026-09-14
The net expense ratio is 0.45%. There are no sales loads or redemption fees. In fiscal 2026 the fund paid $535 in broker commissions, 0.0225% of average net assets, and portfolio turnover was 32%.
WDNA Fees and Expenses
Annual operating expenses and sales charges of WDNA. Prospectus, as of June 30, 2025.
| Annual operating expenses | |
|---|---|
| Management fee | 0.45% |
| 12b-1 fee | 0.00% |
| Other expenses | 0.00% |
| Gross expense ratio | 0.45% |
| Fee waiver | — |
| Net expense ratio | 0.45% |
| Sales charges | |
|---|---|
| Max front load | — |
| Max deferred load | — |
| Redemption fee | — |
| Expense limitation in place (N-CEN) | Yes |
| Fees waived or reduced during the year | No |
| Waived fees subject to recoupment | No |
WDNA Costs Over Time
On $10,000 invested in WDNA, assuming 5% a year before costs, total costs come to $299 over 5 years, cutting the return by 0.50% a year. Illustration, not a forecast: it assumes today's net expense ratio throughout (a fee waiver may end).
| $10,000 invested | Sell after 1 year | Sell after 3 years | Sell after 5 years |
|---|---|---|---|
| Value before costs | $10,500 | $11,576 | $12,763 |
| Fund expenses (net expense ratio 0.45%) | $47 | $148 | $259 |
| Trading costs (broker commissions) | $2 | $7 | $13 |
| Lost growth on money paid in costs | $0 | $8 | $27 |
| Total costs | $50 | $163 | $299 |
| Value after costs | $10,450 | $11,413 | $12,464 |
| Impact on return, per year | 0.50% | 0.50% | 0.50% |
WDNA Trading Costs
Brokerage costs reported on SEC Form N-CEN for the fiscal year ending June 30, 2026.
- Explicit cost rate (commissions ÷ average net assets): 0.0225%
- Total broker commissions: $535
- Bought from dealers (principal trades, not a cost): $540K
- Portfolio turnover (prospectus): 32%
- Securities on loan, average value: $456K
- Net income from securities lending: $2K (0.091% of average net assets)
WDNA Agency Brokers
Commissions paid.
| Broker | Amount | Share |
|---|---|---|
| CITADEL SECURITIES LLC | $179 | 33.52% |
| J.P. Morgan Securities LLC | $92 | 17.23% |
| MORGAN STANLEY & CO. LLC | $87 | 16.29% |
| BOFA SECURITIES, INC. | $78 | 14.61% |
| GOLDMAN SACHS & CO. LLC | $53 | 9.93% |
| UBS SECURITIES LLC | $22 | 4.12% |
| VIRTU AMERICAS LLC | $18 | 3.37% |
| BARCLAYS CAPITAL, INC. | $3 | 0.56% |
| MACQUARIE CAPITAL (USA), INC. | $2 | 0.37% |
WDNA Dealer Counterparties
Securities bought directly from dealers (principal trades).
| Broker | Amount | Share |
|---|---|---|
| J.P. Morgan Securities LLC | $362K | 67.03% |
| Macquarie Capital (USA) Inc. | $112K | 20.67% |
| Exact Sciences Corporation | $36K | 6.71% |
| SPRINGWORKS THERAPEUTICS, INC. | $19K | 3.47% |
| INSTINET, LLC | $10K | 1.85% |
| CITADEL SECURITIES LLC | $1K | 0.27% |
For information only. Not investment advice: figures are as reported in SEC filings and may contain errors or be out of date. Past performance does not guarantee future results.